Results 151 to 160 of about 37,987 (275)

Update on the use of etanercept across a spectrum of rheumatoid disorders

Biologics: Targets & Therapy, 2008
Bernard CombeService d’Immuno-Rhumatologie, Montpellier, FranceAbstract: Etanercept is a soluble TNF receptor p75 fusion protein which is approved for subcutaneous use (50 mg weekly) in the treatment of patients with active rheumatoid arthritis
Bernard Combe
doaj  

Efficacy and safety of brodalumab in palmoplantar pustulosis: A 68‐week randomized Phase 3 trial

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This open‐label study is a continuation of the 16‐week double‐blind, Phase 3 trial assessing the efficacy and safety of brodalumab 210 mg subcutaneously, till a 68‐week extension period. Continued improvement was seen in the PPPASI 50/75/90 responses, PPPSI scores, PGA 0/1 responses and DLQI. Abstract Background The efficacy and safety of brodalumab in
Masamoto Murakami, Yukari Okubo, Satomi Kobayashi, Natsuko Kikuta, Yoshiumi Ouchi, Kenta Shishido, Tadashi Terui   +6 more
wiley   +1 more source

The metabolomics of psoriatic disease. [PDF]

, 2017
Metabolomics is an emerging new "omics" field involving the systematic analysis of the metabolites in a biologic system. These metabolites provide a molecular snapshot of cellular activity and are thus important for understanding the functional changes ...
Afifi, Ladan, Chang, Hsin Wen, Jeon, Caleb, Lee, Kristina, Liao, Wilson, Trivedi, Megha, Yan, Di   +6 more
core  

Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In this Phase 3 trial of Japanese patients with moderate to severe PPP (NCT05174065), significantly more patients achieved PPPASI‐50 at Week 16 with apremilast versus placebo. Patient‐reported outcomes, including pruritus and pain/discomfort, also showed significantly greater decreases at Week 16 with apremilast versus placebo.
Tadashi Terui, Yukari Okubo, Satomi Kobayashi, Akimichi Morita, Shinichi Imafuku, Yayoi Tada, Masatoshi Abe, Bruce Strober, Melinda Gooderham, Wendy Zhang, Junichiro Shimauchi, Masafumi Yaguchi, Takeshi Kimura, Ryuichi Ogawa, Hamid Amouzadeh, Masamoto Murakami   +15 more
wiley   +1 more source

Phase 1 study of balinatunfib, an oral inhibitor of TNFR1 signal in mild‐to‐moderate psoriasis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Balinatunfib is the first oral, small molecule selective inhibitor of TNFR1 signaling. The results of this study indicate that balinatunfib treatment was tolerable with no serious or severe adverse events in patients with mild‐to‐moderate psoriasis and showed clinical responses.
Nassr Nassr, Ohn A. Chow, Mai Anh Nguyen, Laurent Perrin, Fabienne Schumacher, Frank‐Dietrich Wagner, Caroline Dreis, Amel Lahmar, Markus Kohlmann, Maria Wiekowski, Tiago R. Matos   +10 more
wiley   +1 more source

French guidelines on systemic treatments for moderate‐to‐severe psoriasis in adults: Update 2025

Journal of the European Academy of Dermatology and Venereology, EarlyView.
New 2025 French guidelines update psoriasis management with revised algorithms integrating recent systemic therapies. They recommend methotrexate, adalimumab or ustekinumab as first‐line treatments and provide guidance for special psoriasis forms, comorbidities, pregnancy and long‐term management.
Marie Masson Regnault, Emilie Brenaut, Marie‐Emeline Marniquet, Carla Berthault, Lea Canoen, Clarisse Marcombes, Audrey Melin, Raphaël Ouakrat, Julie Charles, Stephane Mouret, Olivier Potie, Laetitia Penso, Laura Pina Vegas, Guillaume Larid, Marine Roux, Colombe Bougeard, Sandy Sylvain, Clara Labonne, Tania Randriamiarana, Da Hee Pitaud, Floriane Etheve, Jeremy Gottlieb, Laurie Gouillon, Marine Chastagner, Emilie Sbidian, Hélène Aubert, on behalf of the Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie), Hélène Aubert, Marie Masson Regnault, Emilie Brenaut, Emilie Sbidian, Laura Pina Vegas, Laetitia Penso, Jeremy Gottlieb, Marine Roux, Clara Labonne, Tania Randriamiarana, Floriane Etheve, Da Hee Pitaud, Marie‐Emeline Marniquet, Carla Berthault, Clarisse Marcombes, Audrey Melin, Colombe Bougeard, Julie Charles, Olivier Potie, Léa Canoen, Laurie Gouillon, Marine Chastagner, Sandy Sylvain, Guillaume Larid, Raphaël Ouakrat   +51 more
wiley   +1 more source

Delphi consensus: First‐line use of biologics and small molecules in hidradenitis suppurativa

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This Delphi Consensus study identified upgrade criteria for the use of biologics and small molecules as first‐line therapy in hidradenitis suppurativa (HS). European HS experts evaluated 16 clinical scenarios, voting on eligibility for therapy escalation.
Georgios Nikolakis, Erkan Alpsoy, Florian Anzengruber, Matthias Augustin, Falk G. Bechara, Pierre‐André Becherel, Farida Benhadou, Vincenzo Bettoli, Joana Cabete, Raffaele Dante Caposiena Caro, Antonella Di Cesare, Giovanni Damiani, Valentina Dini, Evangelos J. Giamarellos‐Bourboulis, Krisztián Gáspár, Katalin Glasenhardt, Philippe Guillem, Ariela Hafner, Barbara Horvath, John R. Ingram, Vaiva Jarienè, Gregor B. E. Jemec, Alexander Katoulis, Natalia Kirsten, Georgios Kokolakis, Piotr K. Krajewski, Aikaterini I. Liakou, Flavia Manzo Margiotta, Angelo V. Marzano, Antonio Martorell, Lukasz Matusiak, Dillon Mintoff, Alejandro Molina Leyva, Andreas Pinter, Anna Pirogova, Maurizio Podda, Francesca Prignano, Jorge Romani, Marco Romanelli, Elia Rosi, Samed Sahin, Ditte M. L. Saunte, Sylke Schneider‐Burrus, Mariano Suppa, Jacek Szepietowski, Andrea Szegedi, Simon Francis Thomsen, Thrasyvoulos Tzellos, Anastasia Trigoni, Hessel H. Van Der Zee, Kelsey Van Straalen, Skaidra Valiukevičiene, Eva Vilarrasa, Esther von Stebut, Christos C. Zouboulis   +54 more
wiley   +1 more source

Bimekizumab plus topical photochemotherapy effective in palmoplantar pustulosis in a patient with hidradenitis suppurativa

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Neda Cramer, Johannes Mohr, Michael P. Schön, Rotraut Mössner   +3 more
wiley   +1 more source

Building the foundations for an international patient‐centred outcomes set for psoriasis: A scoping study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This scoping study refined the first patient‐centred outcome set for psoriasis, involving patient representatives and dermatologists from 22 countries. The proposal includes 18 patient‐relevant outcomes, 2 patient experiences, corresponding outcome measurement instruments and 50 case‐mix variables.
Emma Vyvey, Rani Soenen, Hazel H. Oon, Sicily Mburu, Maren Awici‐Rasmussen, Azura Mohd Affandi, Wayne Gulliver, Siew Eng Choon, Tiago Torres, Allison FitzGerald, Alvaro Gonzalez‐Cantero, Anna López‐Ferrer, Chih‐Hung Lee, Fernando Valenzuela, Julia‐Tatjana Maul, Luis Puig, Masanori Okuse, Mohamed EL‐Komy, Peter Foley, Ron Vender, Wolf‐Henning Boehncke, Josef Pohunek, Ya Hsin Wang, Angela Londoño‐García, Gail Todd, Margarita Velasquez‐Lopera, Mark Lebwohl, Edmund Lau, Marcus Schmitt‐Egenolf, Niels Hilhorst, Spencer Connell, Elfie Deprez, Nanja van Geel, Christopher Griffiths, Peter Van de Kerkhof, Jo Lambert   +35 more
wiley   +1 more source

Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019

, 2020
Bathon, J., Breedveld, F., Burmester, G., Bykerk, V., Crofford, L., Cronstein, B., Dougados, M., Furst, D., Kalden, J., Mariette, X., Mease, P., Melchers, F., Rosenbaum, J., Sieper, J., Smolen, J., Weinblatt, M., Winthrop, K.   +16 more
core   +1 more source